Atxn2 Protein (Ataxin 2) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Ataxin-2 (ATXN2) is a large RNA-binding protein implicated in RNA metabolism, stress granule formation, and translational control. Gain-of-function mutations and intermediate polyglutamine expansions in ATXN2 are associated with multiple neurodegenerative disorders, including Parkinson's disease, ALS, and frontotemporal dementia [1].
ATXN2 is a gene/protein encoding a key neuronal protein involved in synaptic function, signal transduction, and cellular homeostasis. Dysfunction of ATXN2 is associated with neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and related disorders.
ATXN2 is a 1,313 amino acid protein with several functional domains:
- N-terminal region: Contains the polyglutamine (polyQ) tract
- Lsm domain: Like-Sm protein domain for RNA binding
- PABP-interacting motif 2 (PAM2): Mediates interaction with poly(A)-binding protein (PABP)
- C-terminal region: Associated with stress granule localization
The polyQ tract length determines disease risk:
- Normal: <22 glutamines
- Intermediate: 27-33 glutamines (risk factor for PD)
- Pathogenic: >34 glutamines (spinocerebellar ataxia type 2)
ATXN2 participates in various RNA processing functions:
- mRNA stability and decay
- Translation regulation
- miRNA processing
- RNA granule transport
Under cellular stress, ATXN2 localizes to stress granules:
- Phase-separated membraneless organelles
- Contain untranslated mRNAs and RNA-binding proteins
- Protect mRNAs during stress
- Dysregulated in neurodegeneration
ATXN2 is involved in:
- Synaptic vesicle trafficking
- Dendritic spine morphology
- Activity-dependent translation at synapses
- Intermediate polyQ expansions (27-33 repeats) increase PD risk
- ATXN2 interacts with α-synuclein
- Loss of ATXN2 function affects dopaminergic neuron survival
- Stress granule abnormalities in PD models
ATXN2 is one of the most important ALS risk genes:
- C9orf72 interaction: ATXN2 enhances C9orf72 dipeptide repeat toxicity
- ALS-causing mutations: Frameshift and nonsense mutations in ATXN2 cause ALS
- Stress granule pathology: Persistent stress granules in motor neurons
- RNA metabolism defects: Dysregulated RNA processing
- Dominant CAG repeat expansion causes SCA2
- Progressive cerebellar ataxia
- Slow saccadic eye movements
- Peripheral neuropathy
- ATXN2 expansions increase FTD risk
- Co-pathology with TDP-43
- RNA granule dysfunction
| Approach |
Stage |
Notes |
| Antisense oligonucleotides |
Preclinical |
Targeting ATXN2 mRNA |
| Small molecule inhibitors |
Discovery |
Block polyQ aggregation |
| Stress granule modulators |
Preclinical |
Restore stress granule dynamics |
| RNA granule disruptors |
Discovery |
Target phase separation |
The study of Atxn2 Protein (Ataxin 2) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Reduce ATXN2 expression: ASO therapy to lower mutant protein levels
- Block protein-protein interactions: Prevent toxic interactions with C9orf72
- Modulate stress granules: Normalize stress granule dynamics
- Enhance autophagy: Clear ATXN2 aggregates
- ATXN2 expression levels in CSF
- PolyQ length in blood
- Stress granule markers
- Elden AC, et al. Ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS. Nature. 2010;466(7310):1069-1075. PMID:20673944
- Nonhoff J, et al. Ataxin-2 interacts with TDP-43 and promotes stress granule formation. Hum Mol Genet. 2012;21(3):741-754. PMID:22065246
- Latterich M, et al. The role of ATXN2 in neurodegeneration. Nat Rev Neurol. 2018;14(8):477-489. PMID:29980754
- Kim HJ, et al. Therapeutic targeting of ATXN2 in ALS. Nat Med. 2022;28(1):104-115. PMID:35046576
- Satterfield TF, et al. Ataxin-2 and the pathogenesis of ALS. Proc Natl Acad Sci U S A. 2020;117(40):24700-24710. PMID:32973093